Last year, only two percent of the respondents surveyed by Cegedim cited regulatory and compliance issues as a driver of new technology adoption, and six percent said regulatory and compliance was a primary driver of pharmaceutical business model or process change. A lot can happen in a year.
A repeat of the survey, released last week, found that regulatory and compliance issues had jumped to 16% as a driver for new technology adoption. As a motivation for business model or process change, the percentage of respondents citing regulatory and compliance issues (13%) more than doubled this year.
While executive management and strategic planning still represent the top two influences with respect to new technology adoption and changes to business operations, respectively, both categories decreased significantly from last year.
“Spending at pharmaceutical companies is shifting to compliance,” said Angela Miccoli, Cegedim’s president, North America, during a presentation on the data.
Asked about the biggest changes companies are making, 73% cited an increased focus on market access strategies; 63% cited an increased focus on managed markets; and 59% cited a realignment of primary sales forces.
The survey was conducted online, mostly among pharmaceutical executives, managers and directors in sales, marketing, general management and regulatory departments.